Skip to main content
main-content

Rheumatology

Rheumatology

19-07-2019 | Rheumatology | News | Article

Genetic loci influencing asymptomatic hyperuricemia to gout progression identified

A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.

18-07-2019 | Rheumatology | News | Article

Surrogate randomization technique enables triple biologic comparison

Estimated remission and retention rates do not differ significantly among patients with rheumatoid arthritis treated with either certolizumab pegol, abatacept, or biosimilar infliximab, show the results of a surrogate randomized controlled trial.

17-07-2019 | Rheumatology | News | Article

Mild tapering of TNF inhibitors may be appropriate in axSpA

Real-world study results suggest that mild tapering of tumor necrosis factor inhibitors does not influence the probability of achieving inactive disease among patients with axial spondyloarthritis.

15-07-2019 | Rheumatology | News | Article

Vitamin D has potential benefits for people with osteoarthritis

Vitamin D intake is inversely associated with cartilage degeneration among patients with osteoarthritis, and supplementation may have a protective effect, suggests an analysis of data from the Osteoarthritis Initiative.

11-07-2019 | Rheumatology | News | Article

Biologic therapy has paved the way for improved outcomes in JIA

The biologic treatment era has led to “remarkable prognostic improvement,” relative to the methotrexate era, for children with juvenile idiopathic arthritis, show data reported in Arthritis Research & Therapy.

10-07-2019 | Rheumatology | News | Article

Biologic treatment may improve control of PsA-related bone disease

Psoriatic arthritis patients treated with biologic DMARDs have higher bone mass and strength than those not receiving DMARD treatment, suggest findings from a cross-sectional study.

09-07-2019 | Rheumatology | News | Article

Pregnancy outcomes improving for women with SLE

In the past two decades pregnancy outcomes, including in-hospital maternal mortality, have improved among women with systemic lupus erythematosus, but further improvements are needed to reduce risks further, US research shows.

08-07-2019 | Rheumatology | News | Article

RA genetic risk linked to IQ, hyperactivity during childhood

Genetic liability for rheumatoid arthritis is associated with lower IQ and symptoms of hyperactivity and inattention during childhood and adolescence, supporting a link between genetic risk for the condition and neural phenotypes, UK researchers report.

05-07-2019 | Rheumatology | News | Article

Favorable results with TNF inhibitors in Behçet's disease-associated uveitis

The tumor necrosis factor inhibitors adalimumab and infliximab both show good efficacy when used as first biologic agents in patients with refractory uveitis due to Behçet's disease, Spanish research shows.

04-07-2019 | Rheumatology | News | Article

Baricitinib, with optional methotrexate, may be beneficial in RA

Baricitinib monotherapy may be a suitable maintenance strategy for some patients with rheumatoid arthritis, but some may also need methotrexate, suggest findings from a post-hoc analysis.

03-07-2019 | Rheumatology | News | Article

Tanezumab shows analgesic benefits in OA but at a cost

Findings from a phase III trial conducted in the USA suggest that tanezumab improves pain and physical function scores relative to placebo among patients with moderate-to-severe hip or knee osteoarthritis and an inadequate response to analgesics.

02-07-2019 | Rheumatology | News | Article

Support for TNF inhibitor use in patients with entero-Behçet’s disease

People with entero-Behçet’s disease and active ulcerative lesions who are treated with tumor necrosis factor inhibitors, either alone or in combination with corticosteroids, are more likely to experience ulcer cure or improvement than those taking corticosteroids alone, researchers report.

01-07-2019 | Rheumatology | News | Article

OA patients at increased risk for multiple comorbidities

People with osteoarthritis are significantly more likely than those without to have multiple comorbidities, particularly stroke, peptic ulcers, and the metabolic syndrome, show results of a systematic review and meta-analysis of observational data.

28-06-2019 | Rheumatology | News | Article

Glucocorticoid withdrawal an achievable goal in patients with SLE

Glucocorticoid tapering and complete withdrawal can be achieved in patients with systemic lupus erythematosus and may be particularly successful in those with long-term remission or low disease activity, Italian researchers report.

26-06-2019 | Rheumatology | News | Article

Anxiety, depressive symptoms linked to pain and disability in JIA

Anxiety and depressive symptoms are associated with pain and disability but not active joint count or biomarkers of inflammation in adolescents with juvenile idiopathic arthritis, researchers report.

25-06-2019 | Rheumatology | News | Article

Positive secukinumab results for axial manifestations in PsA

Secukinumab improves axial manifestations in patients with psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, primary analysis of the phase III MAXIMISE trial shows.

25-06-2019 | Rheumatology | News | Article

Ixekizumab efficacious in PsA following one or two inadequate anti-TNF responses

Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

24-06-2019 | Rheumatology | News | Article

Fasinumab may be a new option for osteoarthritic pain

The anti‐nerve growth factor monoclonal antibody fasinumab improves pain and function in patients with knee or hip osteoarthritis who have a history of inadequate response or intolerance to analgesics, study findings indicate.

21-06-2019 | Rheumatology | News | Article

Ultra-low rituximab doses may not be appropriate in RA

A randomized trial has failed to demonstrate noninferiority of ultra-low dose rituximab to a standard low dose of the drug in patients with rheumatoid arthritis.

20-06-2019 | Rheumatology | News | Article

KAWAKINRA results support further investigation of anakinra for Kawasaki disease

The interleukin-1 receptor inhibitor anakinra merits further investigation for the treatment of Kawasaki disease, suggest findings from a phase IIa trial presented at the EULAR 2019 congress in Madrid, Spain.

Image Credits